Ignite may be a speculative buying opportunity, however, at present the company should be watched for early signs of improvement. For now, we are looking...
Over the past few months, Paradigm has succumbed to short-term traders repositioning on delayed news regarding Investigational New Drug approval (IND)...
The 2021/22 Budget handed down by Treasurer Josh Frydenberg this week delivered many welcome changes to superannuation. But they introduce confusion...
Crypto is an increasingly dominant topic of conversation among investors, but is it a genuine asset class or the latest in a long list of financial manias?
Invex Therapeutics Limited is in an enviable position, with ample working capital to see the company through the completion of phase 3 clinical trials...
Global Health’s services are deployed in over 1,000 healthcare organisations, supporting in excess of 1.5 million people. The company's solutions include...
Mayfield's current order book has recovered well after COVID-19 with a healthy mix of capital and maintenance, across mining, infrastructure, renewables...
April delivered its best monthly performance in six months to see the S&P/ASX 200 rise by 3.5%, closing less than 2% below its pre-pandemic all-time highs..
If you’re looking for the basics of how to invest like Warren Buffett, the shortest version is to look at this 1985 TV interview, his first apparently...
It makes sense that the cheaper you buy an asset the higher its prospective return will be. However, this is frequently forgotten, with investors often...
XTEK provides high-quality frontline combatant products and tailored solutions to government agencies, law enforcement, military, space, and commercial...
Treasury Wine Estates has been hit hard by the COVID-19 pandemic-related shutdowns, with premium wine sales globally suffering amidst the closure of restaur
Qantas is Australia’s dominant carrier and we see a number of drivers for Qantas over the next few years that can drive strong share price growth for...
Suda Pharmaceuticals Ltd (ASX:SUD) is one of the quiet achievers in the biotech sector that have, until recently, stayed off the radar of most investors...
Login
Please enter your username and password
Wait...
Don't go empty handed
Enter your email address to get reports direct to your inbox